Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Risk of second primary malignancies
2011.10.20
Active substance: lenalidomide
Important information on the risk of second primary malignancies in patients treated with Revlimid® (lenalidomide). Results of the benefit-risk review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN